Abstract:Abstract Background Synonymous mutations have been identified to play important roles in cancer development, although they do not modify the protein sequences. However, relatively little research has specifically delineated the functionality of synonymous mutations in cancer. Results We investigated the nucleotide-based and amino acid-based features of synonymous mutations across 15 cancer types from The Cancer Genome Atlas (TCGA), and revealed novel driver candidates by identifying hotspot mutations. Firstly, synonymous mutations were analyzed between TCGA and 1000 Genomes Project at nucleotide and amino acid levels. We found that C:G → T:A transitions were the most frequent single-base substitutions, and leucine underwent the largest number of synonymous mutations in TCGA due to prevalent C → T transition, which induced the transformation between optimal and non-optimal codons. Next, 97 synonymous hotspot mutations in 86 genes were nominated as candidate drivers with potential cancer risk by considering the mutational rates across different sequence contexts. We observed that non-CpG-island GC transition sequence context was positively selected across most of cancer types, and different sequence contexts under which hotspot mutations occur could be significance for genetic differences and functional features. We also found that the hotspots were more conserved than neutral mutations of hotspot-mutation-containing-genes and frequently happened at leucine. In addition, we mapped hotspots, neutral and non-hotspot mutations of hotspot-mutation-containing-genes to their respective protein domains and found ion transport domain was the most frequent one, which could mediate the cell interaction and had relevant implication for tumor therapy. And the signatures of synonymous hotspots were qualitatively similar with those of harmful missense variants. Conclusions We illustrated the preferences of cancer associated synonymous mutations, especially hotspots, and laid the groundwork for understanding the synonymous mutations act as drivers in cancer.

Cancer Histone Mutations Impact Binding and DNA Repair Processes, Leading to Increased Mutagenesis

Histone Mutations and Cancer

Histone H3 mutations and their impact on genome stability maintenance

Aberrant expression of histone H2B variants reshape chromatin and alter oncogenic gene expression programs

Surprising phenotypic diversity of cancer-associated mutations of Gly 34 in the histone H3 tail

Mechanism of Cancer: Oncohistones in Action

Histone H3.3 and Cancer: A Potential Reader Connection.

Deciphering principles of nucleosome interactions and impact of cancer-associated mutations from comprehensive interaction network analysis

Emerging roles of cancer-associated histone mutations in genomic instabilities

Histone Lysine-to-Methionine Mutation As Anticancer Drug Target

Cancer-associated Histone H3 N-terminal arginine mutations disrupt PRC2 activity and impair differentiation

The role of histone post-translational modifications in cancer and cancer immunity: functions, mechanisms and therapeutic implications

An Analysis of Mutational Signatures of Synonymous Mutations Across 15 Cancer Types.

Genome-wide Mutational Spectra Analysis Reveals Significant Cancer-Specific Heterogeneity

Histone Demethylase Lysine Demethylase 5B in Development and Cancer

Histone H3 Variants in the Multiverse of Cancer

Protein structural context of cancer mutations reveals molecular mechanisms and identifies novel candidate driver genes

Cancer epigenomics: DNA methylomes and histone-modification maps

The Role of Histone Modification in DNA Replication-Coupled Nucleosome Assembly and Cancer

Abstract PR12: Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape

Role of Several Histone Lysine Methyltransferases in Tumor Development